DNA甲基化酶3A在动脉粥样硬化中的作用机制  

Mechanism of DNMT3A in Atherosclerosis

作　　者：闫然 上官艺 仇鑫 李子孝[1,2,3] YAN Ran;SHANGGUAN Yi;QIU Xin;LI Zi-Xiao(Department of Neurology,Beijing Tiantan Hospital,Capital Medical University,Beijing 100070,China;China National Clinical Research Center for Neurological Diseases,Beijing 100070,China;Chinese Institute for Brain Research,Beijing 102206,China)

机构地区：[1]首都医科大学附属北京天坛医院神经病学中心,北京100070 [2]国家神经系统疾病临床医学研究中心 [3]北京脑科学与类脑研究中心

出　　处：《中国卒中杂志》2021年第11期1178-1182,共5页Chinese Journal of Stroke

基　　金：国家自然科学基金项目(82171270,92046016);北京市自然科学基金项目(Z200016);中国医学科学院医学与健康科技创新工程项目(2019-I2M-5-029)。

摘　　要：近来的研究显示,DNA甲基化酶3A(DNA methylase 3 alpha,DNMT3A)在动脉粥样硬化过程中起着重要的调控作用,而动脉粥样硬化是冠心病及缺血性卒中等心脑血管疾病的重要病理基础。体细胞DNMT3A基因突变可能通过多种免疫细胞、作用机制影响动脉粥样硬化的发生、发展过程,是心脑血管疾病一项尚未明确的重要危险因素。本文重点介绍DNMT3A在心脑血管疾病中的作用机制以及其在心脑血管疾病诊疗中的应用前景。DNA methylase 3 alpha(DNMT3A)is an important DNA methylation enzyme.Recent studies have shown that it plays an important role in the regulation of atherosclerosis,which is the important pathological basis of cardiovascular and cerebrovascular diseases(CVD),such as coronary heart disease and ischemic stroke.Somatic DNMT3A mutation may affect the occurrence and development of atherosclerosis through several immune cells and mechanisms,and it is an important risk factor for CVD that has not been fully studied.This article focused on the mechanism of DNMT3A in CVD and its application prospect in the diagnosis and treatment of CVD.

关 键 词：DNA甲基化酶3A 动脉粥样硬化 心脑血管病 作用机制 炎症 

分 类 号：R543.5[医药卫生—心血管疾病]